scholarly journals BRCA2 C-terminal RAD51-binding Domain Confers Resistance to DNA-damaging Agents

Author(s):  
Yasunaga Yoshikawa ◽  
Masami Morimatsu ◽  
Arisa Tanaka ◽  
Ryo Morioka ◽  
Koichi Orino

Abstract Breast cancer type 2 susceptibility (BRCA2) protein is crucial for initiating DNA damage repair after chemotherapy with DNA interstrand cross-linking agents or X-ray irradiation. These treatments induce double-stranded breaks in genomic DNA. BRCA2 contains a C-terminal RAD51-binding domain (CTRBD) that interacts with RAD51-oligomer containing nucleofilaments. RAD51 nucleofilaments are essential for the homologous recombination repair of double-stranded DNA damage. In this study, we investigated the effects of expressing the CTRBD in cells exposed to X-ray irradiation and mitomycin C treatment. Surprisingly, expressing the BRCA2 CTRBD in HeLa cells increased their resistance to X-ray irradiation and mitomycin C. To determine the ability of the BRCA2 CTRBD to mediate DNA damage repair, the endogenous BRCA2 was depleted by shRNA. No significant differences were observed between the sensitivities of the BRCA2-depleted cells with or without expressing BRCA2 CTRBD. Thus, the resistance to X-ray irradiation conferred by the exogenous CTRBD required endogenous BRCA2 expression. To the best of our knowledge, our study is the first to report the ability of the BRCA2 functional domain to confer resistance to X-ray irradiation and mitomycin C treatment. This peptide may be useful in the protection of cells against X-ray irradiation or chemotherapeutic agents.

Oncogene ◽  
2016 ◽  
Vol 35 (45) ◽  
pp. 5905-5915 ◽  
Author(s):  
M Y Shah ◽  
E Martinez-Garcia ◽  
J M Phillip ◽  
A B Chambliss ◽  
R Popovic ◽  
...  

2011 ◽  
Vol 5 ◽  
pp. BCBCR.S8184 ◽  
Author(s):  
Apichart Atipairin ◽  
Adisorn Ratanaphan

BRCA1 is a tumor suppressor protein involved in maintaining genomic integrity through multiple functions in DNA damage repair, transcriptional regulation, cell cycle checkpoint, and protein ubiquitination. The BRCA1-BARD1 RING complex has an E3 ubiquitin ligase function that plays essential roles in response to DNA damage repair. BRCA1-associated cancers have been shown to confer a hypersensitivity to chemotherapeutic agents. Here, we have studied the functional consequence of the in vitro E3 ubiquitin ligase activity and cisplatin sensitivity of the missense mutation D67Y BRCA1 RING domain. The D67Y BRCA1 RING domain protein exhibited the reduced ubiquitination function, and was more susceptible to the drug than the D67E or wild-type BRCA1 RING domain protein. This evidence emphasized the potential of using the BRCA1 dysfunction as an important determinant of chemotherapy responses in breast cancer.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1390-1390
Author(s):  
Ritika Dutta ◽  
Bruce Tiu ◽  
Arya Kaul ◽  
Bryan Mitton ◽  
Kathleen M. Sakamoto

Abstract CREB (cAMP Response Element Binding Protein) is a nuclear transcription factor that plays a critical role in regulating myeloid cell proliferation and differentiation. CREB is overexpressed in Acute Myeloid Leukemia (AML) cells from the majority of AML patients at diagnosis, and CREB overexpression is associated with a poor prognosis.Transgenic mice overexpressing CREB in myeloid cells develop myelodysplasia/myeloproliferative neoplasms. CREB also cooperates with other oncogenes, such as Sox4, to induce transformation to AML. Knockdown of CREB inhibits AML proliferation but does not affect normal hematopoietic stem cell activity, establishing the crucial role of CREB in AML cell growth and survival. In vitro, CREB overexpression leads to increased resistance to apoptosis in AML cells. Thus, we hypothesized that increased CREB expression confers chemoresistance, as this may represent one reason that patients with high CREB levels have worse prognoses and relapse following therapy. Previous studies have demonstrated that chemotherapy resistance can result from increased DNA damage repair activity, but CREB has never been implicated in these DNA damage repair processes, nor has CREB even been described as an important transcriptional regulator of DNA damage repair genes. The goal of this study was to characterize whether CREB expression confers chemoresistance through regulation of DNA repair genes in AML cells. Firstly, we established that CREB expression levels correlate with chemoresistance by treating KG-1 cells engineered to express lower and higher levels of CREB with etoposide and doxorubicin, both chemotherapy drugs used to treat AML. Cells with CREB overexpression had increased viability compared to CREB knockdown cells after treatment with both chemotherapies at a range of concentrations. To investigate the underlying mechanism, we performed CREB chromatin immunoprecipitation and RNA-seq following small molecule CREB inhibition to identify the sets of genes that are regulated by CREB in AML cells and whose expression levels are sensitive to CREB inhibition. Out of 88 DNA damage repair genes found to be CREB-bound, 41 exhibited at least a 2-fold change in expression after CREB inhibition. qPCR was performed to determine whether the expression of DNA damage repair genes were proportional to CREB levels. Transcription of ATM, ATR, RAD54L, and RAD51, genes important in sensing and repairing DNA damage, were coordinately regulated with CREB expression. ATM, ATR, RAD54L, and RAD51 were reduced by approximately 42.0%±0.1%, 44.8%±0.1%, 40.2%±0.1%, and 27.9%±0.1% respectively in CREB knockdown cells (p≤0.05). Reduced expression of these genes also had a functional consequence. CREB knockdown cells initiated a lesser DNA damage repair response in response to etoposide treatment, as determined by measured phospho-H2AX levels, compared to wild-type CREB-expressing cells. Conversely, cells with CREB overexpression exhibited the strongest DNA damage repair response following etoposide treatment. Taken together, these data demonstrate that CREB overexpression has a protective effect against DNA damage and confers chemoresistance, likely through upregulation of DNA damage repair genes. Future studies will seek to determine if small molecule inhibition of CREB can reduce the transcription of DNA damage repair genes and thus sensitize AML cells to chemotherapeutic agents. Disclosures No relevant conflicts of interest to declare.


2006 ◽  
Vol 26 (3) ◽  
pp. 976-989 ◽  
Author(s):  
Joanna Wesoly ◽  
Sheba Agarwal ◽  
Stefan Sigurdsson ◽  
Wendy Bussen ◽  
Stephen Van Komen ◽  
...  

ABSTRACT Homologous recombination is a versatile DNA damage repair pathway requiring Rad51 and Rad54. Here we show that a mammalian Rad54 paralog, Rad54B, displays physical and functional interactions with Rad51 and DNA that are similar to those of Rad54. While ablation of Rad54 in mouse embryonic stem (ES) cells leads to a mild reduction in homologous recombination efficiency, the absence of Rad54B has little effect. However, the absence of both Rad54 and Rad54B dramatically reduces homologous recombination efficiency. Furthermore, we show that Rad54B protects ES cells from ionizing radiation and the interstrand DNA cross-linking agent mitomycin C. Interestingly, at the ES cell level the paralogs do not display an additive or synergic interaction with respect to mitomycin C sensitivity, yet animals lacking both Rad54 and Rad54B are dramatically sensitized to mitomycin C compared to either single mutant. This suggests that the paralogs possibly function in a tissue-specific manner. Finally, we show that Rad54, but not Rad54B, is needed for a normal distribution of Rad51 on meiotic chromosomes. Thus, even though the paralogs have similar biochemical properties, genetic analysis in mice uncovered their nonoverlapping roles.


2010 ◽  
Vol 60 (1) ◽  
pp. 157-161 ◽  
Author(s):  
G. Schettino ◽  
M. Ghita ◽  
K. M. Prise

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 366-OR
Author(s):  
GRACE H. YANG ◽  
JEE YOUNG HAN ◽  
SUKANYA LODH ◽  
JOSEPH T. BLUMER ◽  
DANIELLE FONTAINE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document